Regeneron pairs with BioNTech on melanoma immunotherapy
Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other checkpoint inhibitors. The two companies will carry out a phase 2 trial of Libtayo (cemiplimab) alongside BioNTech’s… Read More »Regeneron pairs with BioNTech on melanoma immunotherapy
